Literature DB >> 15943491

Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures.

Uwe Wollina1, Helga Konrad.   

Abstract

Botulinum toxin A (BTXA) has become a widely used drug in cosmetic dermatology, not only to treat focal hyperhidrosis but also hyperkinetic facial lines, platysma bands, décolleté bands, and other skin features. The spectrum of possible adverse effects of BTXA is broad but fortunately those that have been observed with cosmetic use of this product are generally mild and transient. The major tools for preventing adverse effects from BTXA are knowledge and skill. Use of correct injection techniques is mandatory since most unwanted effects are caused by incorrect technique. Knowledge of the target structures, e.g. the facial and extrafacial muscles, allows physicians to select the optimal dose, time and technique. The most common adverse effects are pain and hematoma. In the periocular region, lid and brow ptosis are important adverse effects. Adverse effects such as pain, hematoma, ecchymosis, and bruising may also occur in the upper and lower face and at extrafacial sites. Other possible adverse effects seen in other indications that the user of BTXA in cosmetic dermatology should be wary of include induction headaches and possible interaction with concomitant medications. Induction of neutralizing antibodies due to cosmetic BTXA treatment has not been observed. This article also outlines recommendations regarding use of BTXA. Of these, the most important for avoiding most unwanted adverse effects are the proper techniques of dilution, storage, and injection, as well as the careful exclusion of patients with any contraindications. Pain, hematoma, ecchymosis, and bruising can be prevented by cooling the skin before and after BTXA injection. Upper lid ptosis may be partly corrected using apraclonidine or phenylephrine eyedrops. If simple rules relating to the indications for and application of BTXA are followed, this is a safe and effective drug in cosmetic dermatology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943491     DOI: 10.2165/00128071-200506030-00001

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  12 in total

1.  The use of a contact cooling device to reduce pain and ecchymosis associated with dermal filler injections.

Authors:  Mark S Nestor; Glynis R Ablon; Mark A Stillman
Journal:  J Clin Aesthet Dermatol       Date:  2010-03

Review 2.  [Management and prevention of adverse events in esthetic interventions].

Authors:  D Hartmann; M Heppt; G G Gauglitz
Journal:  Hautarzt       Date:  2015-10       Impact factor: 0.751

Review 3.  [New botulinum toxins for aesthetic dermatology : A comprehensive review].

Authors:  A Patil; M Kassir; U Wollina; M Goldust
Journal:  Hautarzt       Date:  2021-04-06       Impact factor: 0.751

4.  [Side effects in aesthetic medicine. Spectrum, management and avoidance].

Authors:  U Wollina; A Goldman; C Naoum
Journal:  Hautarzt       Date:  2013-03       Impact factor: 0.751

5.  Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action.

Authors:  Uwe Wollina
Journal:  J Cutan Aesthet Surg       Date:  2008-01

6.  Pharmacological sphincterotomy for chronic anal fissures by botulinum toxin a.

Authors:  Uwe Wollina
Journal:  J Cutan Aesthet Surg       Date:  2008-07

Review 7.  Facial rejuvenation for middle-aged women: a combined approach with minimally invasive procedures.

Authors:  Alberto Goldman; Uwe Wollina
Journal:  Clin Interv Aging       Date:  2010-09-23       Impact factor: 4.458

8.  Botulinum toxin type A for the management of glabellar rhytids.

Authors:  Anne Marie Tremaine; Jerry L McCullough
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-07

9.  Complications of minimally invasive cosmetic procedures: prevention and management.

Authors:  Lauren L Levy; Jason J Emer
Journal:  J Cutan Aesthet Surg       Date:  2012-04

Review 10.  Perioral rejuvenation: restoration of attractiveness in aging females by minimally invasive procedures.

Authors:  Uwe Wollina
Journal:  Clin Interv Aging       Date:  2013-09-02       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.